GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New Immune-Boosting drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC